30 students admitted to Entrepreneurship in Biotechnology so far for Fall ‘21. 20 of the 30 are women. Good news for the future of biotechnology.
@Columbia
#Codiak partners with $JAZZ to develop #exosome therapies for hard-to-treat cancers. The deal includes therapies against NRAS and STAT3 & $56 million up front. @BioCentury's @Jennie_Walters reports: https://t.co/SY6jjwSggJ
A decision by #CFIUS to neither clear nor initiate review proposed $2.1B takeout of $ECYT by $NVS provides little clarity as to how far it will tread into biotech turf. @Jennie_Walters talks to multiple lawyers to read the tea leaves in @BioCentury Extra https://t.co/MsfuzBh4fi
FDA picks @flatironhealth's Amy Abernethy for No. 2 spot. @SGottliebFDA told @BioCentury he expects Abernethy to evaluate how FDA can advance its policies in real-world evidence (RWE) as the top thought leader in the U.S. in her field. https://t.co/NrdXsWXEft
Biogen ending a Nav1.7 inhibitor pain program after a Phase IIb miss. $BIIB saw stronger 3Q18 Spinraza sales than Street expected. And Biogen partner Eisai will present more Phase II data for Alzheimer's disease candidate BAN2401 Thursday: https://t.co/95m39kwzHB
ICYMI: $AKAO furnished data from its discontinued LpxC inhibitor program for @pewtrusts' antibiotic research platform against Gram-negative infections. Pew's in similar data-sharing talks with other companies https://t.co/BtDhfQVA1s
Pretty exciting to have my story on @WideTrial and its expanded access program featured in the @politico Prescription PULSE newsletter today! Click here for the full story: https://t.co/PccpjruZ8P
ICYMI: See how new @USTreasury rules expanding #CFIUS could adversely impact foreign investment in U.S. biotechs -- in this week's @BioCentury https://t.co/y00vV3ykMK
The week saw a trio of biotech IPOs miss their price targets, but $LOGC and $OSMT stock climbed in initial days of trading. Most IPOs this year have priced within or above proposed ranges. @BioCentury https://t.co/yXNCiot8FH
.@MarkZipkin covers flurry of news on latest in switch-controlled gene therapy -- all coming on heels of $JNJ & $MGTX's deal to develop ribozyme-based gene therapy control switches. @BioCentury https://t.co/sysRecF1Op
Xyphos & @parkerici steer next-gen CAR Ts into solid tumors. Tech involves using a bispecific antibody to bind, activate & tow universal CAR Ts into solid tumors against a tumor-specific target. @BioCentury https://t.co/eroeNfv4DL
.@AtlasMolecular may give ciclopirox another life as a treatment for Günther disease via a stabilization mechanism "very common for many rare diseases," per study author @catbilbao@CICbioGUNE. https://t.co/bI79D7PxgC
$JNJ has stalled development of lumicitabine (AL-8176), an antiviral compound key to its $1.75B acquisition of Alios BioPharma in 2014. Delay relates to new preclinical data for the clinical asset, J&J told @BioCentury: https://t.co/9hyL8xWH8k